Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | F13A1 | P00488 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16602099 | 0.90 | ALDH1A1 (0.67) | KDM4EF13A1SMN1; SMN2ALDH1A1GLA | |
| SCHEMBL15359162 | 0.86 | MAPT (0.59) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL1695076 | 0.85 | SMN1; SMN2 (0.66) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL22145338 | 0.84 | ALDH1A1 (0.62) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL8233676 | 0.84 | MAPT (0.65) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL10592850 | 0.84 | KDM4E (0.84) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1804701 | 0.83 | NPC1 (0.58) | SMN1; SMN2ALDH1A1GLARAB9ANPC1 | |
| SCHEMBL8393893 | 0.83 | CNR1 (0.61) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL14521463 | 0.83 | KMT2A (0.65) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL20718868 | 0.82 | ALDH1A1 (0.60) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | claimed |
| CN-117886701-A | Full-continuous preparation method of 4-nitrophenethylamine | 爱斯特（成都）生物制药股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| CN-112630347-A | HPLC analysis method of 4-nitrophenylethylamine | 杭州华东医药集团浙江华义制药有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-0713483-B1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-6030985-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | disclosed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | disclosed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | KDM4E 2756/4885F13A1 24/4885SMN1; SMN2 374/4885 |
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | KDM4E 1022/4885F13A1 2697/4885SMN1; SMN2 2417/4885 |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | KDM4E 951/4885F13A1 2802/4885SMN1; SMN2 1278/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | KDM4E 1706/4885F13A1 320/4885SMN1; SMN2 3648/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | KDM4E 951/4885F13A1 2802/4885SMN1; SMN2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.